Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Our formulation is very easy to manufacture compared to existing formulations, in addition to being better for the patient therefore making the MET4 ideal for licensing," said Dr. Max Arella, President of Spencer Pharmaceutical Inc. "The licensing for our Met4 to these companies could yield substantial financial results in the very short term for our company and can be the driving force in making Spencer a world class pharmaceutical," further added Dr. Arella.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
BOSTON, MA--(Marketwire - 10/25/10) - Spencer Pharmaceutical Inc. (Pinksheets:SPPH - News) announced today that it has begun licensing talks with several other pharmaceuticals to manufacture and distribute its Met4 formula in their respective regions.
According to management, the company has signed confidentiality agreements with several companies and has begun talks over the distribution and formulations of its MET4 and Ibuprofen formulations as well as the co-development of several new formulations. The company expects to be in a position to sign a memorandum of understanding and or licensing agreements on or before February 10, 2011.
SPPH :
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
Contact:
Spencer Pharmaceutical Inc.Dr. Max Arella, President, 1+ 617-973-5017orSmallCapVoice.comStuart T. Smith, 512-267-2430info@smallcapvoice.com
spph :
AUSTIN, Texas--(BUSINESS WIRE)-- SmallCapVoice.com, Inc. announced today that a new audio interview featuring Spencer Pharmaceutical Inc. (Pinksheets:SPPH) is now available. The interview can be heard here http://smallcapvoice.com/blog/10-22-10-audio-interview-with-spencer-pharmaceutical-inc-pink-sheets-spph.
SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and client information sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit http://www.smallcapvoice.com/services.html.
thats great to hear. i think this company has the patential to go far, plus with the prs that came out, there mindset and goals will be strong
back up and running green, looking better now
this is very important, with the technology and brains of Dr. Max Arella, President of Spencer Pharmaceutical, this company can grown and develope. so we could have new medications for heart diseases. the achivments are strong and being tested.
Dr. Max Arella, President of Spencer Pharmaceutical Inc. (Pink Sheets: SPPH) joined us at SmallCapVoice.com to explain how Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
The Company recently announced that it has applied for a Level 1 certificate with the International Council for Corporate Governance (ICCG). The certificate application is a 2 step process.
A New Audio Interview Featuring Dr. Max Arella, President of Spencer Pharmaceutical Inc., is now at SmallCapVoice.com
AUSTIN, Texas--(BUSINESS WIRE)-- SmallCapVoice.com, Inc. announced today that a new audio interview featuring Spencer Pharmaceutical Inc. (Pinksheets:SPPH) is now available
A New Audio Interview Featuring Dr. Max Arella, President of Spencer Pharmaceutical Inc., is now at SmallCapVoice.com
AUSTIN, Texas--(BUSINESS WIRE)-- SmallCapVoice.com, Inc. announced today that a new audio interview featuring Spencer Pharmaceutical Inc. (Pinksheets:SPPH) is now available
consolidating lets get a move on here.
these people are briliant as we can all tell and so far thier plan has been expanding and growing. world wide
Bid Ask Day's Range
0.32 0.34 0.34 - 0.41
volume 70k
Throughout his career, he has written 76 scientific publications, 24 scientific reports for research contracts as well as 28 chapters in books and summaries of techniques. He has been invited to give 52 international conferences, has presented 206 scientific communications and has submitted 3 patents. Mr. Arella is fluent in English, French and Italian. He is also a member of the board of directors of an OTCBB company (Protokinetix) and served in many advisory boards of public traded companies during the past fifteen years.
looks like volume is steady and price is low, good time to get in.
President & CEO - Max Arella, Ph.D.
For the past twenty five years, Dr. Arella has acted as a private consultant advising clients and businesses with technological and scientific development, innovative technology transfer and commercial development from university bench top to commercial developments. He acted as the president of a privately held Biotech company that successfully achieved business deals.
From 1993 to 1998 , Dr. Arella was elected twice as chairman of the Virology Research Center of the Armand-Frappier Institute/University of Quebec (the "IAF") during which he held the responsibility of managing both the research and the teaching programs (M.Sc. and Ph.D). From 1984 to 1993 Dr. Arella was scholar, assistant professor and professor of Virology at IAF as well as adjunct professor at the School of Graduate Studies of the University of Montreal. He also served as president of the professor association from 1989 to 1992.His academic research is mainly based in the fields of molecular biology, fundamental aspects and applications of the double-stranded RNA virus, as well as amplification systems for the analysis of human and animal viruses, and cancer markers.
0.375 ? 0.005 (1.35%)
Volume: 62,665 @ 10:48:27 AM ET
Bid Ask Day's Range
0.34 0.375 0.34 - 0.41
holding strong.
Missions
Spencer is currently focusing on the development of 2 patented applications (ready for Human trial) in the treatment of Central Nervous System diseases and of Diabetes:
L’Institut National des Sciences Appliquées de Rouen (INSA Rouen) has discovered a new technology in the challenging area of drugs delivered to the Central Nervous System through an innovative approach that allows the crossing of the blood-brain barrier and dramatically reducing the side effects of drugs used for neurological diseases.
L’Universite du Québec à Montréal (UQAM) has discovered how to control the release of existing therapeutics molecules in order to increase their bio-availability and systemic efficacy.
Our goal is to develop a portfolio of pro-drugs with the ability to outclass the current commercial drugs. We aim to establish long-term, mutually beneficial relationships will all our partners and clients.
pharmaceuticals always have the everything it takes to being succeccful
Spencer Pharmaceuticals is a newly formed public company specializing in the identification of new drug delivery applications. A global player in the biopharmaceutical market, Spencer has forged relationships with two highly respected laboratories located in Universities throughout the world. Our focus is on newly patented formulation of existing drugs from the incubation to the developmental stages or newly synthesized drugs able to cross the blood-brain barrier. Our partners are experienced researchers providing the Company years of research, ''now ready for the drug-development status''.
"As an OTC Pinksheet listed company we have high standards in our reporting and transparency procedures corporately as well as scientifically," stated Dr. Max Arella, President of Spencer Pharmaceutical Inc., furthermore, "we believe it is our corporate duty to continually improve our already high standards of reporting to investors with our ultimate goal being the improved value of our company to our current shareholders and future investors," added Dr. Arella.
Level 1 certificate with the International Council for Corporate Governance (ICCG). The certificate application is a 2 step process. First a questionnaire to be filled out by a company executive is completed. This is reviewed by the ICCG Audit Committee. Then the Companies Executives and Board of Directors will review and in conjunction with ICCG adopt a code of ethics prepared with ICCG. If satisfactory, ICCG will then issue a certification with all details
looks like potential is on our side here. looking solid
Business Overview
We are building a portfolio of companies and technologies that mitigate negative environmental and health consequences that arise from the production of energy and the consumption of resources. On November 2, 2007, through our wholly owned subsidiary, Mantra Energy Alternatives Ltd., we entered into a technology assignment agreement with 0798465 BC Ltd. whereby we acquired 100% ownership of an invention for the electro-reduction of carbon dioxide.
Our mission is to develop and commercialize alternative energy technologies and services to enable the sustainable consumption, production and management of resources on residential, commercial and industrial scales. We plan to develop or acquire technologies and services which include electrical power system monitoring technology, wind farm electricity generation, online retail of environmental sustainability solutions through a carbon reduction marketplace, and media solutions to promote awareness of corporate actions that support the environment. To carry out our business strategy we intend to acquire or license from third parties technologies that require further development before they can be brought to market. We also intend to develop such technologies ourselves, and we anticipate that to complete commercialization of some technologies we will enter into joint ventures, partnerships, or other strategic relationships with third parties who have expertise that we may require. We also plan to enter into formal relationships with consultants, contractors, retailers and manufacturers who specialize in the areas of environmental sustainability in order to carry out our online retail strategy.
Results of Operations for the Period From January 22, 2007 (Date of Inception) to August 31, 2010 and for the Three Months Ended August 31, 2010.
We have had limited operational history since our inception on January 22, 2007. From our inception on January 22, 2007 to August 31, 2010 we have generated $19,898 in revenues. For the three months ended August 31, 2010 we did not generate revenues compared to revenues generated of $13,798 during the same period in 2009. Since our inception on January 22, 2007 to August 31, 2010, we have an accumulated deficit of $5,199,246. We anticipate that we will incur substantial losses over the next year and our ability to generate additional revenues in the next 12 months remains uncertain.
Long-lived Assets
In accordance with ASC 360, "Property, Plant and Equipment", we test long-lived assets or asset groups for recoverability when events or changes in circumstances indicate that their carrying amount may not be recoverable. Circumstances which could trigger a review include, but are not limited to:
significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed significantly before the end of its estimated useful life. Recoverability is assessed based on the carrying amount of the asset and its fair value which is generally determined based on the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset, as well as specific appraisal in certain instances. An impairment loss is recognized when the carrying amount is not recoverable and exceeds fair value.
Liquidity and Capital Resources
As of August 31, 2010, we had $10,226 cash in our bank accounts and a working capital deficit of $1,099,418. As of August 31, 2010, we had total assets of $85,945 and total liabilities of $1,119,472.
From January 22, 2007 (date of inception) to August 31, 2010, we raised net proceeds of $2,586,984 in cash from the issuance of common stock, $66,078 from loans payable and $250,000 from proceeds from the issuance of convertible debentures for a total of $2,903,062 of cash provided by financing activities for the period.
We received net cash of $88,200 from financing activities for the three months ended August 31, 2010 compared to $193,544 for the same period in 2009.
We used net cash of $82,299 in operating activities for the three months ended August 31, 2010 compared to $196,864 for the same period in 2009. We used net cash of $2,737,201 in operating activities for the period from January 22, 2007 (date of inception) to August 31, 2010.
We did not use any cash in investing activities for the three months August 31, 2010 and for the three months August 31, 2009.
During the three months ended August 31, 2010 we had an increase of $5,901 in our cash position compared to a decrease of $3,320 for the same period in 2009. Our monthly cash requirements for three month period ended August 31, 2010 was approximately $27,433 compared to $65,621 for the same period in 2009. At our current cash position and if this cash requirement continues, we do not have sufficient cash to cover our expenses for one month.
Results of Operations for the Period From January 22, 2007 (Date of Inception) to August 31, 2010 and for the Three Months Ended August 31, 2010.
We have had limited operational history since our inception on January 22, 2007. From our inception on January 22, 2007 to August 31, 2010 we have generated $19,898 in revenues. For the three months ended August 31, 2010 we did not generate revenues compared to revenues generated of $13,798 during the same period in 2009. Since our inception on January 22, 2007 to August 31, 2010, we have an accumulated deficit of $5,199,246. We anticipate that we will incur substantial losses over the next year and our ability to generate additional revenues in the next 12 months remains uncertain.
very important for our future
New Alternatives (NALFX), established in 1982, is one of the pioneers of green investing. Through investments in alternative energy, biofuels, and fuel-cell technology, their returns exceeded 33 percent in 2007.
Business Overview
We are building a portfolio of companies and technologies that mitigate negative environmental and health consequences that arise from the production of energy and the consumption of resources. On November 2, 2007, through our wholly owned subsidiary, Mantra Energy Alternatives Ltd., we entered into a technology assignment agreement with 0798465 BC Ltd. whereby we acquired 100% ownership of an invention for the electro-reduction of carbon dioxide.
Our mission is to develop and commercialize alternative energy technologies and services to enable the sustainable consumption, production and management of resources on residential, commercial and industrial scales. We plan to develop or acquire technologies and services which include electrical power system monitoring technology, wind farm electricity generation, online retail of environmental sustainability solutions through a carbon reduction marketplace, and media solutions to promote awareness of corporate actions that support the environment. To carry out our business strategy we intend to acquire or license from third parties technologies that require further development before they can be brought to market. We also intend to develop such technologies ourselves, and we anticipate that to complete commercialization of some technologies we will enter into joint ventures, partnerships, or other strategic relationships with third parties who have expertise that we may require. We also plan to enter into formal relationships with consultants, contractors, retailers and manufacturers who specialize in the areas of environmental sustainability in order to carry out our online retail strategy.
This quarterly report on Form 10-Q contains forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology including "could", "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" and the negative of these terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially.
While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested in this report.
this company has potential.
OUR MISSION TOWARD DEFENDING CYBERSECURITY:
LIGATT Security International is dedicated to being the Nation’s leading provider of hi-tech crime investigations, protecting our clients against Black Hat Hacking one CPU at a time.
LIGATT Security has steadily built a reputation as one of the Nation’s premier hi-tech security companies and is recognized as a leader in computer security and cyber-crime investigation. What makes LIGATT Security truly unique is that we are never content to rest on that reputation. We are a company of innovators continually striving to reach new heights of quality and accomplishment. The difference between LIGATT and our competition is evident. While the “typical” computer security company offers only computer security, LIGATT Security maintains state-of-the-art capabilities to address all your home and/or business security and surveillance needs with two separate, dedicated divisions: Computer Security and Hi-Tech Crime Investigations.
Here are some of the computer security issues and needs for which LIGATT Security provides professional equipment, education and training:
About Plimus
Founded in 2001, Plimus is headquartered in California's Silicon Valley. The company has close to a decade's worth of proven experience in the e-commerce and payment fields and has consistently demonstrated high growth. Plimus is regarded as one of the most innovative and effective business platforms in the world for online sales of digital products and services. Plimus is totally committed to helping e-businesses grow and develop by using Plimus' total service platform with its built-in marketing, networking and community features to generate new revenues and higher profitability.
Plimus sellers offer some of the most widely-known and respected titles in the business and more are being added every day! Using the Plimus Affiliate Program not only gains you access to these titles; it also takes the hassle out of your business, and provides you all the tools you need to be successful.
$0.005
Change ? 0.003 (150.00%)
Bid 0.005
Ask 0.0055
Volume 4,812,423
Days Range 0.0026 - 0.006
huge profits
Utilizing Plimus will permit anyone to become an affiliate of the company, allowing them to sell LIGATT's products and services at their own websites. Affiliates will be able to add links on their websites to almost any of LIGATT's products and services, making it easier for their customers to click a link to purchase online. In addition to the affiliate's receiving discounts on selling LIGATT products, they also will receive residuals between 20%-40% when customers renew their services with LIGATT.
Becoming an affiliate of Plimus is fast, easy, has many benefits, and does not require a person to use a credits card, or Pay Pal.
200% up and looking great as we speak! company has alot to offer
For more information about EGOC visit: www.energy1corp.com
Forward-looking Statement:
Please be advised that statements made herein, other than historical data, constitute forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those stated or implied by such forward-looking statements. The potential risks and uncertainties include, among others, potential volatility in the company's stock price, increased competition, customer acceptance of new products and services to be offered by the company, and uncertainty of future revenue and profitability and fluctuations in its quarterly operating efforts.